´Ý±â
TaKaRa
Á¦Ç°¸í/Á¦Ç°ÄÚµå
Å°¿öµå°Ë»ö
°Ë»ö
´Ý±â
  • °í°´Áö¿ø 
  • ¾÷¹«¾È³»¦¢Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢02-2081-2510
  • Email     ¦¢support@takara.co.kr
  • ´ëÀüÁö»ç 
  • ¾÷¹«¾È³»¦¢´ëÀü/ÃæûÁö¿ª ÁÖ¹®, Á¦Ç°¹®ÀÇ
  • ÀüÈ­¹øÈ£¦¢042-828-6525
  • Email     ¦¢tkbd@takara.co.kr
  • ¾÷¹«½Ã°£¾È³»
  • [ Æò¡¡¡¡ÀÏ ] 09 : 00 ~ 18 : 00 ¦¢ [ Á¡½É½Ã°£ ] 12 : 00 ~ 13 : 00
  • Å䡤ÀÏ¿äÀÏ, °øÈÞÀÏÀº ÈÞ¹«ÀÔ´Ï´Ù.


NEWS
 Á¦¸ñ : [°øÁö] ¿Â¶óÀμ¼¹Ì³ª (11/22): È¿À²ÀûÀÎ ½Å¾à°³¹ßÀ» À§ÇÑ °³¼±µÈ Àΰ£ °£¼¼Æ÷ ¸ðµ¨
ÀÛ¼ºÀÏ : 2017.11.15
 ÀÛ¼ºÀÚ : ´ÙÄ«¶óÄÚ¸®¾Æ

<¿Â¶óÀμ¼¹Ì³ª-10ź>

È¿À²ÀûÀÎ ½Å¾à°³¹ßÀ» À§ÇÑ °³¼±µÈ Àΰ£ °£¼¼Æ÷ ¸ðµ¨

-Advanced primary & iPS derived hepatocyte model by cellartis-

 

 ½Å¾à°³¹ß ´Ü°è¿¡¼­ drug metabolism È®ÀÎ ¹× µ¶¼º Å×½ºÆ®¸¦ À§ÇØ »ç¿ëµÇ´Â assay model Áß human primary hepatocyte modelÀº °¡Àå ±¤¹üÀ§ÇÏ°Ô »ç¿ëµÇ¸ç ADME/Tox ¿¬±¸ÀÇ gold standard·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ÇÏÁö¸¸ human primary hepatocyte modelÀ» »ç¿ëÇÏ´Â ½ÇÇèÀº primary hepatocyteÀÇ ÂªÀº ¹è¾ç±â°£°ú assay window, Á¦ÇÑµÈ source, lot-to-lot variationµîÀÇ ¸¹Àº Á¦¾àÀÌ ÀÖ¾ú½À´Ï´Ù.
º» ¼¼¹Ì³ª¿¡¼­´Â ±âÁ¸ÀÇ primary hepatocyte model¿¡¼­ ºÒ°¡´É Çß´ø Hepatitis virus infection, chronic toxicity study¸¦ À§ÇØ 4ÁÖ°£ Àå±â¹è¾çÀÌ °¡´ÉÇÑ human primary hepatocyte medium, ´ëÇü assay ¹× ½Å¾à screening¸ñÀûÀ¸·Î ´ë·®»ý»êÀÌ °¡´ÉÇÑ human iPS derived hepatocyteµî È¿À²ÀûÀÎ ½Å¾à°³¹ßÀ» À§ÇÑ °³¼±µÈ Àΰ£ °£¼¼Æ÷ ¸ðµ¨À» ¼Ò°³ÇÕ´Ï´Ù!

 

  ¡Ü Á¦¸ñ: È¿À²ÀûÀÎ ½Å¾à°³¹ßÀ» À§ÇÑ °³¼±µÈ Àΰ£ °£¼¼Æ÷ ¸ðµ¨

  ¡Ü ÀϽÃ: 2017³â 11¿ù 22ÀÏ(¼ö), ¿ÀÈÄ 3½Ã

  ¡Ü µî·Ï: https://register.gotowebinar.com/register/4793805113146771713

 

 

 

 

 ¸ñ·ÏÀ¸·Î